Isis Pharmaceuticals (ISIS)

Isis’ Ibis Biosciences division made significant commercial progress during the quarter, securing key contracts and expanding its intellectual property portfolio.

·                  Ibis received a purchase order from a U.S. government agency for the commercial sale of two Ibis T5000 Biosensor Systems.  The systems will be used for forensics research.

·                  Ibis received a contract, valued at up to $1.9 million, from a U.S. government agency to perform analysis of up to 10,000 samples in its Ibis T5000 Assay Services Laboratory.

·                  Ibis was awarded a patent that broadly covers the method employed by the Ibis T5000 Biosensor System for identification and characterization of bacterial pathogens.

·                  Ibis’ manufacturing partner, Bruker Daltonics, introduced the Ibis T5000 Biosensor System into the European market.  This followed the earlier signing of a collaboration agreement under which Bruker will be responsible for instrument manufacturing and installation, order processing and support services for the Ibis T5000 Biosensor System.

·                  Ibis successfully completed the first phase of its Challenge Grant from the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health, and has been granted funding for subsequent phases that provide for the installation of an Ibis T5000 Biosensor System at Johns Hopkins University Medical Center.